Forecast horizon — calibration-scored at resolution.
By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.
TL;DR · AI-generated
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray et al. · New England Journal of Medicine · 2014
· openalex W2113698123 · s2 9ca73cac
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1253
By 2028, quadruple therapy (ACEi/ARNI + BB + MRA + SGLT2i) will be the default HFrEF regimen in US registries.
0.1524
The PARADIGM-HF trial's stated primary conclusion — Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalization vs. enalapril in HFrEF. — replicates in independent cohorts.
0.1589
By 2028, SGLT2 inhibitors will be prescribed for ≥70% of eligible HFrEF patients at guideline-adherent cardiology practices.
0.1871
LCZ696 will demonstrate superiority over enalapril in reducing cardiovascular death or heart failure hospitalization across diverse real-world HFrEF populations, including those underrepresented in PARADIGM-HF.
0.2054
LCZ696 reduces the risk of hospitalization for heart failure by 21% compared to enalapril in patients with NYHA class II–IV HFrEF.
0.2100
Recent follow-up analyses of PARADIGM-HF are confirming the original effect size in real-world data.